Archives: 2020-10-08

PIER MARIA FORNASARI
2020-10-08

A large-scale Multi-omic Analysis shows neutrophil degranulation, vessel damage, platelet activation and degranulation, blood coagulation and complement activation are responsible for COVID-19 Severity

RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities and outcomes were performed and published on Cell Systems Quantified transcripts, proteins, metabolites, and lipids were associated with clinical outcomes in a curated relational database, uniquely enabling systems analysis and cross-ome correlations to molecules and patient

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-07

COVID-19 transmission rebounds quickly after physical distancing rules are relaxed

Across the U.S., the relaxation of statewide physical distancing measures that are designed to control the COVID-19 pandemic frequently resulted in an immediate reversal of public health gains against SARS-CoV-2, the virus that causes the disease, researchers from Massachusetts General Hospital (MGH) and colleagues reported. Looking at data from all 50 states and the District

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-07

Experts reaction to Barrington Declaration,open letter arguing against lockdown policies and for ‘Focused Protection’.

An open letter has been published, arguing against lockdown policies and for ‘Focused Protection’. Here are responses of some actual top scientists to the herd immunity declaration from other scientists (many of whom have never published a peer-reviewed paper on Covid-19). Dr Julian Tang, Honorary Associate Professor in Respiratory Sciences, University of Leicester, said: “Having

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-07

Sarilumab use in severe SARS-CoV-2 pneumonia. IL-6 blockade inhibits neutrophil recruitment and innate immune response harm.

Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. In this paper, published on EClinicalMedicine are described the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU)

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-06

Prevalence and prognostic value of Delirium as the initial presentation of COVID-19 in the elderly with dementia: An Italian retrospective study

Delirium may be one of the presenting symptoms of COVID-19, complicating diagnosis and care of elderly patients with dementia. The autors aim to identify the prevalence and prognostic significance of delirium as the sole onset manifestation of COVID-19 in a retrospective single-centre study based on review of medical charts, conducted during the outbreak peak (March

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-06

Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19

The contribution of CD4 + T cells to protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown. In this paper it’s presented single-cell transcriptomic analysis of >100,000 viral antigen-reactive CD4 + T cells from 40 COVID-19 patients. In hospitalized patients compared to non-hospitalized patients, were found increased proportions of cytotoxic follicular helper (T FH

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-01

COVID-19 and Heart Failure With Preserved Ejection Fraction

The more common manifestation in the COVID-19 era may be HFpEF related primarily to the unmasking of subclinical HFpEF and secondarily to the development of new HFpEF following infection with SARS-CoV-2. Patients with preexisting cardiovascular disease (CVD) who develop coronavirus disease 2019 (COVID-19) have worse outcomes than patients without CVD.Infection with severe acute respiratory syndrome

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-01

Fewer than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed.

Fewer than 10 percent of the U.S. adult population formed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the pandemic, according to a study published online Sept. 25 in The Lancet. Shuchi Anand, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a cross-sectional

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-10-01

New randomized clinical trial suggests Hydroxychloroquine failure even as a COVID19 preventative in healthcare workers

In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Despite promising early reports and strong in vitro performance, Hydroxychloroquine (HCQ) has become the major therapeutic disappointment of the COVID pandemic. Research

Read More

No Comments InCovid-19